T1	Treatment 11 83	intravenous iron combined with low-dose recombinant human erythropoietin
T2	Treatment 244 311	parenteral iron and recombinant human erythropoietin-β (rHuEPO-β)
T3	Treatment 575 586	C (control)
T4	Treatment 596 671	IE (200 mg of iron sucrose intravenously over 1 hr and 3000 IU of rHuEPO-β
T5	Treatment 1683 1726	with parenteral iron and low-dose rHuEPO-β
